ES2033086T3 - Un procedimiento para la preparacion de una composicion farmaceutica. - Google Patents

Un procedimiento para la preparacion de una composicion farmaceutica.

Info

Publication number
ES2033086T3
ES2033086T3 ES198989300856T ES89300856T ES2033086T3 ES 2033086 T3 ES2033086 T3 ES 2033086T3 ES 198989300856 T ES198989300856 T ES 198989300856T ES 89300856 T ES89300856 T ES 89300856T ES 2033086 T3 ES2033086 T3 ES 2033086T3
Authority
ES
Spain
Prior art keywords
procedure
preparation
pharmaceutical composition
aqueous
fluids
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES198989300856T
Other languages
English (en)
Spanish (es)
Inventor
Kozo Cno Sankyo Company Limited Kurihara
Masaru Cno Sankyo Company Limited Murano
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sankyo Co Ltd
Original Assignee
Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP63183127A external-priority patent/JP2632010B2/ja
Application filed by Sankyo Co Ltd filed Critical Sankyo Co Ltd
Application granted granted Critical
Publication of ES2033086T3 publication Critical patent/ES2033086T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
ES198989300856T 1988-01-29 1989-01-27 Un procedimiento para la preparacion de una composicion farmaceutica. Expired - Lifetime ES2033086T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP1912588 1988-01-29
JP11163988 1988-05-10
JP63183127A JP2632010B2 (ja) 1988-01-29 1988-07-22 シクロスポリン製剤

Publications (1)

Publication Number Publication Date
ES2033086T3 true ES2033086T3 (es) 1993-03-01

Family

ID=27282507

Family Applications (1)

Application Number Title Priority Date Filing Date
ES198989300856T Expired - Lifetime ES2033086T3 (es) 1988-01-29 1989-01-27 Un procedimiento para la preparacion de una composicion farmaceutica.

Country Status (8)

Country Link
US (1) US4990337A (OSRAM)
EP (1) EP0327280B1 (OSRAM)
AU (1) AU609242B2 (OSRAM)
CA (1) CA1326995C (OSRAM)
DE (1) DE68900991D1 (OSRAM)
ES (1) ES2033086T3 (OSRAM)
GR (1) GR3004611T3 (OSRAM)
HK (1) HK35697A (OSRAM)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5639724A (en) 1984-07-24 1997-06-17 Sandoz Ltd. Cyclosporin galenic forms
GB2222770B (en) * 1988-09-16 1992-07-29 Sandoz Ltd Pharmaceutical compositions containing cyclosporins
US6007840A (en) * 1988-09-16 1999-12-28 Novartis Ag Pharmaceutical compositions comprising cyclosporins
US5342625A (en) * 1988-09-16 1994-08-30 Sandoz Ltd. Pharmaceutical compositions comprising cyclosporins
US7081445B2 (en) * 1989-02-20 2006-07-25 Novartis Ag Cyclosporin galenic forms
US5294604A (en) * 1989-12-20 1994-03-15 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of treating ocular diseases by periocular administration of cyclosporine A or G
DK0448091T3 (da) * 1990-03-23 1999-05-03 Yoshitomi Pharmaceutical Farmaceutisk præparat indeholdende et i ringe grad vandopløseligt medikament
WO1992020795A1 (en) * 1991-05-17 1992-11-26 Cetus Oncology Corporation INHIBITOR OF NF-λB TRANSCRIPTIONAL ACTIVATOR AND USES THEREOF
US6262022B1 (en) 1992-06-25 2001-07-17 Novartis Ag Pharmaceutical compositions containing cyclosporin as the active agent
HK1004520A1 (en) 1992-05-13 1998-11-27 Novartis Ag Ophthalmic compositions containing a cyclosporin
PT589843E (pt) 1992-09-25 2002-04-29 Novartis Ag Composicoes farmaceuticas contendo ciclosporinas
WO1994008538A1 (fr) * 1992-10-22 1994-04-28 Aktsionernoe Obschestvo 'olvik' Membrane oculaire medicinale et son procede de production
JP3862273B2 (ja) † 1993-04-20 2006-12-27 ノバルティス アクチエンゲゼルシャフト 経口投与用シクロスポリン含有新規製剤
DE4322826A1 (de) * 1993-07-08 1995-01-12 Galenik Labor Freiburg Gmbh Pharmazeutisches Präparat
US20020099067A1 (en) * 1993-07-08 2002-07-25 Ulrich Posanski Pharmaceutical compositions for sparingly soluble therapeutic agents
EP1033128B2 (en) 1993-09-28 2011-11-23 R.P. Scherer GmbH Soft gelatin capsule manufacture
PH31594A (en) * 1993-09-30 1998-11-03 Janssen Pharmaceutica Nv Oral formulations on an antifungal.
FR2711982B1 (fr) * 1993-11-02 1996-01-19 Saint Gobain Vitrage Canal de transfert et de conditionnement de verre en fusion.
EP0788346B9 (en) * 1994-03-18 2007-02-14 Supernus Pharmaceuticals, Inc. Emulsified drug delivery systems
US5474979A (en) * 1994-05-17 1995-12-12 Allergan, Inc. Nonirritating emulsions for sensitive tissue
KR970704464A (ko) 1994-11-03 1997-09-06 가이슐러 에리히, 데커 카를-루드빅 간단한 조성 및 높은 생물 유효성을 갖는 경구 투여용의 신규 사이클로스포린 제형 및 이의 제조방법(Novel cyclosporine preparation forms for oral administration of simple composition and high bio-availability, and process for producing them)
US5824638A (en) * 1995-05-22 1998-10-20 Shire Laboratories, Inc. Oral insulin delivery
US5962019A (en) * 1995-08-25 1999-10-05 Sangstat Medical Corporation Oral cyclosporin formulations
US5766629A (en) 1995-08-25 1998-06-16 Sangstat Medical Corporation Oral cyclosporin formulations
US5834017A (en) * 1995-08-25 1998-11-10 Sangstat Medical Corporation Oral cyclopsporin formulations
US5827822A (en) * 1996-03-25 1998-10-27 Sangstat Medical Corporation Cyclosporin a formulations as nanoparticles
EP0760237A1 (en) * 1995-08-30 1997-03-05 Cipla Limited Oil-in-water microemulsions
DE19549852B4 (de) 1995-11-29 2009-06-04 Novartis Ag Cyclosporin enthaltende Präparate
CZ288631B6 (cs) * 1996-01-18 2001-08-15 Galena, A. S. Léčivé přípravky s obsahem cyklosporinu
US5858401A (en) * 1996-01-22 1999-01-12 Sidmak Laboratories, Inc. Pharmaceutical composition for cyclosporines
US5660858A (en) * 1996-04-03 1997-08-26 Research Triangle Pharmaceuticals Cyclosporin emulsions
ES2252780T3 (es) 1996-08-22 2006-05-16 Jagotec Ag Composiciones que comprenden microparticulas de sustancias insolubles en agua y metodo para su preparacion.
US7255877B2 (en) * 1996-08-22 2007-08-14 Jagotec Ag Fenofibrate microparticles
US6465016B2 (en) 1996-08-22 2002-10-15 Research Triangle Pharmaceuticals Cyclosporiine particles
DE19882037T1 (de) 1997-01-30 1999-12-16 Novartis Ag Hartgelatinekapsel, die im wesentlichen ölfreie pharmazeutische Zusammensetzungen enthält
DE19724605A1 (de) * 1997-06-11 1998-12-17 Sueddeutsche Kalkstickstoff Hydrophile, homogene Monogycerid-Formulierungen und Verfahren zu deren Herstellung
US6187747B1 (en) 1997-09-08 2001-02-13 Panacea Biotech Limited Pharmaceutical composition comprising cyclosporin
IN188719B (OSRAM) * 1997-09-08 2002-11-02 Panacea Biotec Ltd
US6346511B1 (en) 1997-09-08 2002-02-12 Panacea Biotec Limited Pharmaceutical composition comprising cyclosporin
US6008191A (en) * 1997-09-08 1999-12-28 Panacea Biotec Limited Pharmaceutical compositions containing cyclosporin
EP1039893B1 (en) 1997-12-10 2011-02-02 Cyclosporine Therapeutics Limited Pharmaceutical compositions containing an omega-3 fatty acid oil
DE19810655A1 (de) * 1998-03-12 1999-09-16 Univ Eberhard Karls Arzneimittel mit einem Gehalt an Ciclosporin
US6979456B1 (en) 1998-04-01 2005-12-27 Jagotec Ag Anticancer compositions
CA2333648C (en) 1998-05-29 2008-10-21 Rtp Pharma Inc. Thermoprotected microparticle compositions and process for terminal steam sterilization thereof
EP0976394A1 (en) * 1998-07-30 2000-02-02 Biosearch Italia S.p.A. New injectable formulations
IL143197A0 (en) 1998-11-20 2002-04-21 Rtp Pharma Inc Dispersible phospholipid stabilized microparticles
JP2002531515A (ja) 1998-12-11 2002-09-24 ファーマソリューションズ・インコーポレイテッド 水に難溶性の薬剤のための自己乳化組成物
US6447806B1 (en) 1999-02-25 2002-09-10 Novartis Ag Pharmaceutical compositions comprised of stabilized peptide particles
US6057289A (en) * 1999-04-30 2000-05-02 Pharmasolutions, Inc. Pharmaceutical composition comprising cyclosporin in association with a carrier in a self-emulsifying drug delivery system
CN1174741C (zh) * 1999-09-21 2004-11-10 Rtp药品公司 生物活性物质的表面改性微粒组合物
US6720001B2 (en) 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
WO2001032143A1 (en) * 1999-11-02 2001-05-10 Cipla Ltd. A pharmaceutical composition for the administration of water-insoluble pharmaceutically active substances and a process for preparation thereof
US7732404B2 (en) * 1999-12-30 2010-06-08 Dexcel Ltd Pro-nanodispersion for the delivery of cyclosporin
GB0008785D0 (en) * 2000-04-10 2000-05-31 Novartis Ag Organic compounds
US8586094B2 (en) * 2000-09-20 2013-11-19 Jagotec Ag Coated tablets
ES2372746T3 (es) * 2000-09-20 2012-01-26 Jagotec Ag Micropartículas de fibrato estabilizadas.
EP2116228A1 (en) * 2001-10-19 2009-11-11 Isotechnika Inc. Novel cyclosporin analog microemulsion preconcentrates
US6979672B2 (en) 2002-12-20 2005-12-27 Polichem, S.A. Cyclosporin-based pharmaceutical compositions
US20050059583A1 (en) 2003-09-15 2005-03-17 Allergan, Inc. Methods of providing therapeutic effects using cyclosporin components
US7135455B2 (en) * 2004-11-15 2006-11-14 Allergan, Inc Methods for the therapeutic use of cyclosporine components
US7151085B2 (en) 2004-11-15 2006-12-19 Allergan, Inc. Therapeutic methods using cyclosporine components
WO2006102157A1 (en) * 2005-03-21 2006-09-28 Ivax Pharmaceuticals S.R.O. Crystallization inhibitor and its use in gelatin capsules
GB2451811A (en) 2007-08-09 2009-02-18 Ems Sa Delivery composition for solubilising water-insoluble pharmaceutical active ingredients
AU2012229236B2 (en) 2011-03-11 2017-05-18 Beth Israel Deaconess Medical Center, Inc. Anti-CD40 antibodies and uses thereof
KR102479225B1 (ko) 2014-09-26 2022-12-20 더 케무어스 컴퍼니 에프씨, 엘엘씨 설폰화 플루오르화, 비-플루오르화 또는 부분 플루오르화 우레탄
DK3307322T3 (da) 2015-09-04 2021-04-19 Primatope Therapeutics Inc Humaniserede anti-cd40-antistoffer og anvendelser deraf

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE149197C (OSRAM) * 1902-10-24
US2865859A (en) * 1956-11-09 1958-12-23 Irwin I Lubowe Solubilizing of mineral, vegetable, animal oils for cosmetic, pharmaceutical and industrial purposes
US3678149A (en) * 1970-01-26 1972-07-18 Samuel J Prigal Method of enhancing the action of a medicament
DE2907460A1 (de) * 1978-03-07 1979-09-13 Sandoz Ag Neue resorbierbare galenische kompositionen
CH641356A5 (en) * 1979-02-27 1984-02-29 Sandoz Ag Pharmaceutical compositions containing cyclosporin
JPS5921613A (ja) * 1982-07-28 1984-02-03 Takeda Chem Ind Ltd 直腸投与製剤
DE3372705D1 (en) * 1982-04-30 1987-09-03 Takeda Chemical Industries Ltd Pharmaceutical composition and its use
US4659696A (en) * 1982-04-30 1987-04-21 Takeda Chemical Industries, Ltd. Pharmaceutical composition and its nasal or vaginal use
US4474751A (en) * 1983-05-16 1984-10-02 Merck & Co., Inc. Ophthalmic drug delivery system utilizing thermosetting gels
BE897724A (fr) * 1983-09-09 1984-01-02 Mallien Denis Systeme de communication selective, bidirectionnelle, par radio, entre un poste de commande et plusieurs postes de travail
DE3339236A1 (de) * 1983-10-28 1985-05-09 Bayer Ag Arzneimittelzubereitung
US4612193A (en) * 1983-12-23 1986-09-16 Del Laboratories, Inc. Sty ointment and method of using the same
US4722914A (en) * 1984-05-30 1988-02-02 Motorola Inc. Method of making a high density IC module assembly
EP0365044A3 (en) * 1984-08-02 1990-08-22 Sandoz Ag Novel pharmaceutical use of (nva)2-cyclosporine
US4649047A (en) * 1985-03-19 1987-03-10 University Of Georgia Research Foundation, Inc. Ophthalmic treatment by topical administration of cyclosporin
US4839342A (en) * 1987-09-03 1989-06-13 University Of Georgia Research Foundation, Inc. Method of increasing tear production by topical administration of cyclosporin

Also Published As

Publication number Publication date
DE68900991D1 (de) 1992-04-23
HK35697A (en) 1997-03-27
US4990337A (en) 1991-02-05
EP0327280A1 (en) 1989-08-09
AU2885389A (en) 1989-08-03
AU609242B2 (en) 1991-04-26
CA1326995C (en) 1994-02-15
GR3004611T3 (OSRAM) 1993-04-28
EP0327280B1 (en) 1992-03-18

Similar Documents

Publication Publication Date Title
ES2033086T3 (es) Un procedimiento para la preparacion de una composicion farmaceutica.
ATE72629T1 (de) Cyclosporin enthaltende pharmazeutische zubereitung.
PT850046E (pt) Microemulsoes para utilizacao como veiculos para administracao de compostos activos
ES2157975T3 (es) Soluciones farmaceuticas con solubilidad mejorada.
SE8504945L (sv) Farmaceutiska kompositioner innehallande antracyklinglykosider
MX9203504A (es) Complejo agente: lipido activo de alta proporcion.
ES8602404A1 (es) Metodo de producir complejos solubles en agua de principios activos insolubles en agua y fosfolipidos
ES2131573T3 (es) Procedimiento para el replegamiento de igf-i a una conformacion activa.
AR003933A1 (es) Micelas mixtas, composiciones acuosas que las contienen, procedimiento para la obtencion de las micelas mixtas y empleo de las micelas mixtas.
ES2075468T3 (es) Vehiculos de suministro de farmacos suspendidos en un portador perfluorado no acuoso.
DE69211691D1 (de) Pharmazeutische formulierung und pharmazeutisches verfahren
DE3575927D1 (de) Purinderivate, verfahren zu ihrer herstellung und pharmazeutische zubereitung.
AR224111A1 (es) Derivados de 1-oxido de acido penicilanico,desprovistos de actividad terapeutica,utiles como intermediarios en la preparacion de 1,1-dioxido de acido penicilanico farmaceuticamente activos,procedimiento para preparar dichos intermediarios y procedimiento para preparar los 1,1-dioxidos de acido penicilanico farmaceuticamente activos partiendo de dichos intermediarios
RU93032613A (ru) Фармацевтический препарат для лечения пациентов с пролонгированным временем коагуляции, способ лечения пациентов, применение epi ингибитора для получения фармацевтического препарата
PE38097A1 (es) NUEVA FORMA CRISTALINA DEL ACIDO 7-([1a, 5a, 6a]-6-AMINO-3-AZABICICLO[3.1.0]HEX-3-IL)-6-FLUOR-1-(2,4-DIFLUOROFENIL)-1,4-DIHIDRO-4-OXO-1,8-NAFTIRIDIN-3-CARBOXILICO ANHIDRO, SAL DEL ACIDO METANOSULFONICO
DK98089A (da) Medikament-lipid-systemer med lav toxicitet
CU22836A3 (es) Sistema de gel de nimesulida para uso tópico
DE3586457D1 (de) Solubilisierungsverfahren im moment der anwendung eines aktiven lipophilen prinzipes in waessriger loesung zum zweck der intravenoesen verabreichung.
ES459244A1 (es) Un procedimiento para la fabricacion de preparados oftalmi- cos de emision lenta
MY110074A (en) Pharmacuetical formulation.
NO900972D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive naftalen-derivater.
AR005724A1 (es) Derivados de ureido biologicamente activos utiles en el tratamiento de esclerosis multiple
ES2057528T3 (es) Pdgf-a, pdgf-aa, pdgf-ab, procedimientos de preparacion y medicamentos que los contienen.
JPS6485990A (en) Antihypertestoeronemia agent
NO900942D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive azacyklooktadien-derivater.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 327280

Country of ref document: ES